Biomarkers for amyotrophic lateral sclerosis

Area of Science:

• Neuroscience
• Biomarker Discovery
• Clinical Neurology

Background:

• Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with limited treatment options.
• Current ALS diagnosis relies heavily on clinical symptoms.
• A promising pipeline of potential treatments is emerging for ALS.

Purpose of the Study:

• To review recent developments in ALS biomarker research and applications over the past two years.
• To discuss the utility of biomarkers in diagnosis, prognosis, and clinical trials for ALS.
• To suggest future directions and needs in ALS biomarker research.

Main Methods:

• Review of recent scientific literature on ALS biomarkers.
• Analysis of diagnostic and prognostic utility of established and novel biomarkers.
• Evaluation of biomarker applications in clinical trials and routine diagnostics.

Main Results:

• Neurofilament utility as a general marker for axoneuronal degeneration in ALS is further confirmed.
• Disease-specific biomarkers for genetic ALS variants (e.g., SOD1, C9orf72) show advancements.
• Novel biomarkers demonstrate encouraging results, though early in development and clinical establishment.

Conclusions:

• Biomarkers are increasingly integrated into routine ALS diagnostics and clinical trials.
• Continued progress in discovering and implementing biomarkers is essential for advancing ALS treatment.
• Biomarkers are crucial for targeting novel therapies and evaluating outcomes in ALS.